CRIS Current Research Information System

ROSELLINI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.324
NA - Nord America 1.770
EU - Europa 1.016
SA - Sud America 220
AF - Africa 132
Continente sconosciuto - Info sul continente non disponibili 132
Totale 6.594
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.678
SG - Singapore 962
CN - Cina 810
VN - Vietnam 703
IT - Italia 369
HK - Hong Kong 280
KR - Corea 170
BR - Brasile 161
NL - Olanda 141
BD - Bangladesh 139
DE - Germania 90
IN - India 86
SE - Svezia 70
FR - Francia 62
CA - Canada 52
GB - Regno Unito 52
CI - Costa d'Avorio 48
FI - Finlandia 47
JP - Giappone 42
SC - Seychelles 35
IE - Irlanda 34
ZA - Sudafrica 32
RU - Federazione Russa 30
CH - Svizzera 29
PH - Filippine 24
AR - Argentina 21
AT - Austria 20
TH - Thailandia 20
JO - Giordania 17
ID - Indonesia 16
BG - Bulgaria 15
PL - Polonia 13
CL - Cile 12
JM - Giamaica 9
MX - Messico 9
CO - Colombia 8
ES - Italia 8
IQ - Iraq 7
LT - Lituania 7
TW - Taiwan 7
BE - Belgio 6
EC - Ecuador 6
PK - Pakistan 6
CR - Costa Rica 5
TR - Turchia 5
GT - Guatemala 4
NI - Nicaragua 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
DZ - Algeria 3
KG - Kirghizistan 3
KZ - Kazakistan 3
PE - Perù 3
PT - Portogallo 3
TG - Togo 3
UA - Ucraina 3
UY - Uruguay 3
AZ - Azerbaigian 2
DO - Repubblica Dominicana 2
GP - Guadalupe 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
KE - Kenya 2
ML - Mali 2
MY - Malesia 2
OM - Oman 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
IR - Iran 1
KW - Kuwait 1
KY - Cayman, isole 1
LB - Libano 1
LC - Santa Lucia 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MU - Mauritius 1
MZ - Mozambico 1
NO - Norvegia 1
PR - Porto Rico 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
TN - Tunisia 1
Totale 6.462
Salva come PNG Salva come JPEG
Città #
Singapore 689
Hefei 295
Hong Kong 256
Ashburn 248
San Jose 206
Hanoi 188
Ho Chi Minh City 181
Seoul 165
Santa Clara 113
Council Bluffs 112
Beijing 88
Bologna 70
Boardman 62
Los Angeles 57
New York 55
Abidjan 48
Chandler 40
Milan 37
Dublin 33
São Paulo 32
Tokyo 32
Da Nang 31
Dallas 31
Lauterbourg 29
Buffalo 28
Helsinki 28
Johannesburg 28
Bengaluru 27
Guangzhou 25
Haiphong 23
Bern 22
Redondo Beach 22
Amsterdam 21
Nuremberg 19
Rome 18
Shanghai 18
Amman 17
Castel Maggiore 17
Frankfurt am Main 16
Biên Hòa 15
Hyderabad 15
Lappeenranta 15
Montreal 15
Chicago 14
Brooklyn 13
Munich 13
Orem 13
Sofia 13
Turin 13
Vienna 13
Phoenix 12
Falkenstein 11
London 11
Tongling 11
Atlanta 10
Fairfield 10
Ninh Bình 10
Princeton 10
Hải Dương 9
Southend 9
Warsaw 9
Boston 8
Columbus 8
Nanjing 8
Toronto 8
Florence 7
Houston 7
Jakarta 7
Quận Bình Thạnh 7
Rimini 7
Shenzhen 7
Thái Nguyên 7
Zhengzhou 7
Bari 6
Brussels 6
Can Tho 6
Changsha 6
Chennai 6
Madison 6
Manchester 6
Manila 6
Moscow 6
Paris 6
Phú Thọ 6
Stockholm 6
Thái Bình 6
Bangkok 5
Berlin 5
Enschede 5
Hoofddorp 5
Kingston 5
Mexico City 5
Modena 5
Quezon City 5
Quảng Ngãi 5
Quận Hai 5
Redmond 5
San Francisco 5
San José 5
San Polo di Torrile 5
Totale 3.927
Salva come PNG Salva come JPEG
Nome #
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 236
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 213
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 180
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 180
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 179
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 178
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 178
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 176
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 171
Bone targeting agents in patients with metastatic prostate cancer: State of the art 169
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 167
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 167
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 160
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 158
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 155
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 153
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 138
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 133
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 128
Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning 126
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 126
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 126
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 114
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations 110
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 108
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study 108
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges 107
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 101
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 100
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 96
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 94
Treating prostate cancer by antibody-drug conjugates 87
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 87
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 87
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 87
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 85
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 84
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 82
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 80
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 79
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 78
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 78
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 76
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 74
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 73
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 71
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 70
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 69
Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma 68
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study 65
Current androgen receptor antagonists under investigation for resistant prostate cancer 65
Advancements of investigational agents for renal cell carcinoma: what clinical progress have we seen in the last 5 years? 58
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 56
Re: First-line Therapy for Advanced Non-Clear Cell Renal Cell Carcinoma. A Systematic Review and Meta-analysis 53
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 45
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 45
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 44
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 44
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 43
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 43
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 35
Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2EV project 26
KIM-1 and beyond: emerging biomarkers for adjuvant immunotherapy in clear cell renal cell carcinoma 22
Totale 6.594
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.180
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.180
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202292 0 0 1 3 2 1 8 21 6 3 33 14
2022/2023365 5 15 7 17 36 35 21 19 95 11 55 49
2023/2024228 19 36 21 14 18 27 7 17 13 16 24 16
2024/20251.514 72 153 104 87 166 61 91 56 39 122 220 343
2025/20264.026 366 531 342 318 383 140 404 144 649 287 185 277
2026/2027357 134 155 68 0 0 0 0 0 0 0 0 0
Totale 6.594